公开(公告)号：US20180169079A1

公开(公告)日：2018-06-21

申请号：US15895100

申请日：2018-02-13

Applicant: SANTEN PHARMACEUTICAL CO., LTD.

Inventor： Naveed SHAMS ,  Henk-Andre KROON ,  Hisashi KAWATA ,  Noriko KAWABATA

IPC: A61K31/444 ,  A61K9/00

CPC classification number: A61K31/444 ,  A61K9/0048 ,  A61P27/02 ,  A61P27/06

Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.

公开(公告)号：US20160324838A1

公开(公告)日：2016-11-10

申请号：US15212592

申请日：2016-07-18

Applicant: SANTEN PHARMACEUTICAL CO., LTD.

Inventor： Naveed SHAMS ,  Henk-Andre KROON ,  Hisashi KAWATA ,  Noriko KAWABATA

IPC: A61K31/444 ,  A61K9/00

CPC classification number: A61K31/444 ,  A61K9/0048

Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.

Abstract translation: 提供了用于治疗或预防青光眼或高眼压症的药物制剂，其包含0.0003至0.01％（w / v）异丙基（6 - {[4-（吡唑-1-基）苄基]（吡啶-3-基磺酰基） 氨基甲基}吡啶-2-基氨基）乙酸酯或其盐。 药物制剂具有优异的眼内压降效果，可用作青光眼或高眼压症的治疗或预防剂或眼压降低剂。

公开(公告)号：US20220054466A1

公开(公告)日：2022-02-24

申请号：US17521031

申请日：2021-11-08

Applicant: Santen Pharmaceutical Co., Ltd.

Inventor： Naveed SHAMS ,  Henk-Andre KROON ,  Hisashi KAWATA ,  Noriko KAWABATA

IPC: A61K31/444 ,  A61P27/06 ,  A61P27/02 ,  A61K9/00

Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.

公开(公告)号：US20200289483A1

公开(公告)日：2020-09-17

申请号：US16887108

申请日：2020-05-29

Applicant: SANTEN PHARMACEUTICAL CO., LTD.

Inventor： Naveed SHAMS ,  Henk-Andre KROON ,  Hisashi KAWATA ,  Noriko KAWABATA

IPC: A61K31/444 ,  A61P27/06 ,  A61P27/02 ,  A61K9/00

Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.

公开(公告)号：US20190105310A1

公开(公告)日：2019-04-11

申请号：US16211839

申请日：2018-12-06

Applicant: SANTEN PHARMACEUTICAL CO., LTD.

Inventor： Naveed SHAMS ,  Henk-Andre KROON ,  Hisashi Kawata ,  Noriko Kawabata

IPC: A61K31/444 ,  A61P27/02 ,  A61K9/00 ,  A61P27/06

Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.